National guidelines, clinical trials, and quality of evidence.

This publication has 14 references indexed in Scilit:

• The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
  JAMA, 1999
• British Hypertension Society guidelines for hypertension management 1999: summary
  BMJ, 1999
• Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
  New England Journal of Medicine, 1999
• Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial
  The Lancet, 1999
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
  The Lancet, 1998
• Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
  The Lancet, 1997
• Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
  JAMA, 1995
• Recruitment in the Hypertension Detection and Follow-up Program
  Controlled Clinical Trials, 1987
• Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5-Year findings of the hypertension detection and follow-up program.
  Hypertension, 1984
• UK HEART DISEASE PREVENTION PROJECT: INCIDENCE AND MORTALITY RESULTS
  The Lancet, 1983